Adhering too strictly to biomedical thinking about diagnosis can prevent clinicians from empathically engaging with patients and helping them navigate their illness experiences.
AMA J Ethics. 2021; 23(7):E537-541. doi:
10.1001/amajethics.2021.537.
Charles E. Binkley, MD, Michael S. Politz, MA, and Brian P. Green, PhD
If the safe-and-effective standard for judging devices’ potential as therapy or enhancement is inadequate, one might wonder whether BCI regulation should be overseen by the FDA.
AMA J Ethics. 2021; 23(9):E745-749. doi:
10.1001/amajethics.2021.745.